The trial is being conducted under the direction of James Cleary and George Cannon at the University of Wisconsin Carbone Cancer Center (UWCCC).
ProCertus founder, chairman and chief scientific officer William Fahl said the company had worked closely with Cleary and Cannon to identify radiotherapy patient populations in which DermX, when approved, will significantly eliminate some of the side effects of the cancer therapy experience.
ProCertus CEO and Venture Investors MD Paul Weiss said the company has a novel approach to prevent radiodermatitis, and thereby improve the patient’s quality of life.